GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Online Resource  (8)
  • SAGE Publications  (8)
Material
  • Online Resource  (8)
Publisher
  • SAGE Publications  (8)
Person/Organisation
Language
Years
FID
  • 1
    Online Resource
    Online Resource
    Renal outcomes and prognostic factors in patients with type-2 diabetes and chronic kidney disease confirmed by renal biopsy
    SAGE Publications ; 2021
    In:  Therapeutic Advances in Chronic Disease Vol. 12 ( 2021-01), p. 204062232110523-
    Details
    In: Therapeutic Advances in Chronic Disease, SAGE Publications, Vol. 12 ( 2021-01), p. 204062232110523-
    Abstract: To evaluate the renal outcomes and prognostic factors among patients with type-2 diabetes (T2D) and biopsy-confirmed diabetic nephropathy (DN), non-diabetic renal disease (NDRD) and DN mixed with NDRD (MIX). Design and Methods: Patients with both T2D and chronic kidney disease (CKD) who underwent renal biopsy between January 2014 and December 2016 were recruited in this prospective observational study. Participants were divided into DN group, NDRD group, or MIX group according to the baseline pathological diagnosis. The primary endpoint was a composite renal event of end-stage renal disease (ESRD) or ⩾ 40% reduction in estimated glomerular filtration rate (eGFR). Results: Among the 292 participants included, 153 (52.4%) belonged to the DN group, 30 (10.3%) belonged to the NDRD group, and 109 (37.3%) belonged to the MIX group. During the median follow-up of 27 months, the adverse renal events occurred in 132 (44.2%) patients. Compared with NDRD group, the multiple adjusted hazard ratios (HRs) for renal events in patients with DN and MIX groups were 3.900 (95% confidence interval [CI]: 1.103–13.788) and 2.691 (95% CI: 0.662–10.936), respectively. Baseline lower eGFR (HR: 1.159, 95% CI : 1.060–1.266), severe proteinuria (HR: 2.047, 95% CI: 1.227–3.416), lower hemoglobin (HR: 1.170, 95% CI: 1.008–1.267), and a family history of diabetes (HR: 1.138, 95% CI: 1.008–2.285) were independent predictors for adverse renal outcomes in patients with DN. Conclusion: In patients with T2D and CKD, pure DN and MIX group displayed a worse renal prognosis than NDRD group. Worse renal function, severe proteinuria, lower hemoglobin, and a family history of diabetes may be associated with adverse renal outcomes in patients with DN.
    Type of Medium: Online Resource
    ISSN: 2040-6223 , 2040-6231
    URL: Article
    DOI: 10.1177/20406223211052388
    Language: English
    Publisher: SAGE Publications
    Publication Date: 2021
    detail.hit.zdb_id: 2554816-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Early Changes of Serum Interleukin 14α Levels Predicts the Response to Anti-PD-1 Therapy in Cancer
    SAGE Publications ; 2023
    In:  Clinical Medicine Insights: Oncology Vol. 17 ( 2023-01), p. 117955492311633-
    Details
    In: Clinical Medicine Insights: Oncology, SAGE Publications, Vol. 17 ( 2023-01), p. 117955492311633-
    Abstract: Programmed cell death-1 (PD-1) blockade has been shown to confer clinical benefit in cancer patients. Here, we assessed the level of serum interleukin 14α (IL14α) in patients receiving anti-PD-1 treatment. Methods: This prospective study recruited 30 patients with advanced solid cancer who received pembrolizumab treatment in Northern Jiangsu People’s Hospital between April 2016 and June 2018. The western blot analysis was used to assess the expression level of serum IL14α in patients at baseline and after 2 cycles of treatment. Interleukin 14α was performed using the unpaired 2-tailed Student test. The progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method and compared by the log-rank test. Results: The early change of IL14α after 2 cycles of anti-PD-1 therapy was calculated as delta IL14α % change = (IL14α level after 2 cycles − IL14α level before treatment)/IL14α level before treatment × 100%. Receiver operating characteristic (ROC) was analyzed to get a cutoff point of delta IL14α % change as 2.46% (sensitivity = 85.71%, specificity = 62.5%; area under the ROC curve [AUC] = 0.7277, P = .034). Using this cutoff to subgroup the patients, an improved objective response rate was observed in patients with a delta IL14α change higher than 2.46% ( P = .0072). A delta IL14α change over 2.46% was associated with a superior PFS ( P = .0039). Conclusions: Early changes of serum IL14α levels may be a promising biomarker to predict outcomes in patients with solid cancer following anti-PD-1 treatment.
    Type of Medium: Online Resource
    ISSN: 1179-5549 , 1179-5549
    URL: Article
    DOI: 10.1177/11795549231163369
    Language: English
    Publisher: SAGE Publications
    Publication Date: 2023
    detail.hit.zdb_id: 2577877-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Mutational Analyses of the FMR1 Gene in Chinese Pediatric Population of Fragile X Suspects : Low Tolerance for Point Mutation
    SAGE Publications ; 2015
    In:  Journal of Child Neurology Vol. 30, No. 6 ( 2015-05), p. 803-806
    Details
    In: Journal of Child Neurology, SAGE Publications, Vol. 30, No. 6 ( 2015-05), p. 803-806
    Abstract: CGG repeat expansion is the most common cause of fragile X syndrome. Numerous efforts have been made to identify novel mutations in patients with intellectual disability, developmental delay, and/or autism. To evaluate the mutational spectrum in the at-risk Chinese population, 60 pediatric patients presenting fragile X traits but normal-sized CGG repeats were sequenced for all 17 exons and regulatory regions in FMR1. A c.879A 〉 C mutation, reported to alter a neighboring splicing, was detected in a severely retarded male and his normal mother. However, the exon junction appears unaffected. A 237-kb deletion covering the entire FMR1 was identified to cause moderate intellectual disability and marked hyperactivity in an 8-year-old boy. The 5′ and 3′ breakpoints were buried in the surrounding long interspersed and short interspersed elements, respectively. In general, missense mutations do not commonly cause fragile X syndrome, whereas deletions should be considered with caution in patient referrals presenting with developmental delay and/or ordinary retardation.
    Type of Medium: Online Resource
    ISSN: 0883-0738 , 1708-8283
    URL: Article
    DOI: 10.1177/0883073814538508
    Language: English
    Publisher: SAGE Publications
    Publication Date: 2015
    detail.hit.zdb_id: 2068710-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    DOT1L Epigenetically Regulates Autophagy and Mitochondria Fusion in Cell Lines of Renal Cancer
    SAGE Publications ; 2023
    In:  Technology in Cancer Research & Treatment Vol. 22 ( 2023-01)
    Details
    In: Technology in Cancer Research & Treatment, SAGE Publications, Vol. 22 ( 2023-01)
    Abstract: DOT1L, a histone methylase, is overexpression in renal cell cancer. However, the role and detailed molecular mechanism of DOT1L involved in renal cancer development remain unknown. Methods The inhibition of DOT1L was used by SGC0946 and short hairpin RNA silencing. Monodansylcadaverine staining and transmission electron microscope were performed to detect autophagy changes as a result of the inhibition of DOT1L. MitoTracker Red assay was used to analyze mitochondrial morphology. The autophagy markers and mitochondria-related proteins were analyzed by Western blot, qPCR, or immunofluorescence. ChIP assay was performed to demonstrate H3K79me2 is involved in the direct regulation of Farnesoid X receptor transcription. Results DOT1L inhibition increased autophagy activity and promoted mito chondria fusion in cell lines of renal cancer. Inhibition of DOT1L upregulated levels of LC3α/β, P62, MFN1, and MFN2, which contributed to autophagy activity or mitochondria fusion. DOT1L knockdown showed a similar the above process. DOT1L inhibition or silencing resulted in AMP-activated protein kinase activation and mammalian target of rapamycin inhibition. Mechanistically, the DOT1L inhibitor and its short hairpin RNAs decreased the expression of Farnesoid X receptor in a histone methylase-dependent manner. Conclusion We revealed the essential role of Farnesoid X receptor in regulating DOT1L-induced autophagy and mitochondrial fission through the AMP-activated protein kinase/mammalian target of rapamycin pathway in cell lines of renal cancer, which may provide new insights into the pathogenesis of renal cell cancer.
    Type of Medium: Online Resource
    ISSN: 1533-0346 , 1533-0338
    URL: Article
    DOI: 10.1177/15330338231167249
    Language: English
    Publisher: SAGE Publications
    Publication Date: 2023
    detail.hit.zdb_id: 2146365-7
    detail.hit.zdb_id: 2220436-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Estimation of end-of-life electric vehicle generation and analysis of the status and prospects of power battery recycling in China
    SAGE Publications ; 2022
    In:  Waste Management & Research: The Journal for a Sustainable Circular Economy Vol. 40, No. 9 ( 2022-09), p. 1424-1432
    Details
    In: Waste Management & Research: The Journal for a Sustainable Circular Economy, SAGE Publications, Vol. 40, No. 9 ( 2022-09), p. 1424-1432
    Abstract: With the development of the electric vehicle (EV), vehicle end-of-life (EOL) management has become a significant challenge. This study sets two EV sales scenarios (low and high), compares the impact of two battery replacement methods (buying a new vehicle or replacing the battery) on future EOL EV production, and predicts the difference in the amount of EOL EV battery production under two probability functions (normal and Weibull’s distributions). The results show that when the EV power battery is retired and the vehicle owner chooses to buy a new vehicle, the predicted scrap quantity under low sales and high sales (HS) scenarios in 2030 is 4.3 and 5.3 million, respectively. Replacing the battery and continuing to use the vehicle will mean fewer EOL vehicles are generated. Considering the construction of an EOL EV battery recycling management system in China is still in the exploratory period, it is necessary to encourage vehicle owners to replace the battery and continue to use the vehicle. Under a HS scenario, the predicted number of EOL EV batteries in 2030 is 3.8–7.4 million. In the next 10 years, the issue of EV recycling should be raised to the same level as the issue of EV popularisation.
    Type of Medium: Online Resource
    ISSN: 0734-242X , 1096-3669
    URL: Article
    DOI: 10.1177/0734242X221080097
    Language: English
    Publisher: SAGE Publications
    Publication Date: 2022
    detail.hit.zdb_id: 1480483-9
    detail.hit.zdb_id: 46937-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    A novel natural-derived tilapia skin collagen mineralized with hydroxyapatite as a potential bone-grafting scaffold
    SAGE Publications ; 2022
    In:  Journal of Biomaterials Applications Vol. 37, No. 2 ( 2022-08), p. 219-237
    Details
    In: Journal of Biomaterials Applications, SAGE Publications, Vol. 37, No. 2 ( 2022-08), p. 219-237
    Abstract: Collagen is widely used in medical field because of its excellent biocompatibility and bioactivity. To date, collagen for biomedical use is always derived from bovine or swine. The purpose of this study was to evaluate collagen-based biomaterials from non-mammalian donors for bone repair. Thus, tilapia skin collagen-hydroxyapatite (T-col/HAp) scaffolds were fabricated in three different proportions and then cross-linked with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide-N-hydroxysuccinimide (EDC-NHS). The scaffolds were evaluated for their microstructure, chemical and physical properties, mechanical strength and degradability. Then the in vitro responses of bone mesenchymal stem cells (BMSCs) to the scaffolds were investigated in terms of cellular proliferation, differentiation, and mineralization. At last, the scaffolds were implanted into rat skull critical defections to investigate the potential of osteogenic activities. As a result, the pore sizes and the porosities of the scaffolds were approximately 106.67–196.67 μm and 81.5%–66.7%. Pure collagen group showed a mechanical strength of 0.065 MPa, and the mechanical strength was significantly enhanced almost 17 times and 32 times in collagen/HAp ratio 1:4 and 1:9 groups. In vitro studies revealed the most prominent and healthy growth of BMSCs in collagen/HAp ratio 1:4 group. All the scaffolds showed certain osteogenic activities and those loaded with small amount of hydroxyapatite showed the strongest bioactivities. The micro-CT showed that the critical bone defect was almost filled with generated bone 6 months after implantation in collagen/HAp ratio 1:4 group. The biomechanics tests further confirmed the highest generated bone strength was in the collagen/HAp ratio 1:4 group. This study indicated aquatic collagen might be a potential alternative for type I collagen from mammals in bone tissue engineering. The combination of collagen and inorganic materials was also important and appropriate inorganic component loading can achieve both osteogenic quality and osteogenic efficiency to a certain extent.
    Type of Medium: Online Resource
    ISSN: 0885-3282 , 1530-8022
    URL: Article
    DOI: 10.1177/08853282221086246
    Language: English
    Publisher: SAGE Publications
    Publication Date: 2022
    detail.hit.zdb_id: 2072559-0
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Optimization of Electric Bus Scheduling Considering Charging Station Resource Constraints
    SAGE Publications ; 2023
    In:  Transportation Research Record: Journal of the Transportation Research Board
    Details
    In: Transportation Research Record: Journal of the Transportation Research Board, SAGE Publications
    Abstract: The electrification of bus systems is an inevitable trend in sustainable urban development because electric buses do not use fossil fuels and, therefore, do not exacerbate energy shortages. However, because of their limited driving range and the restricted charging station resources, it is crucial to optimize the scheduling and charging plan for electric buses jointly to ensure operational efficiency. This paper studies the electric bus scheduling problem considering charging station resource constraints, including the limited number of chargers and total power output, which are generally simplified in the relevant literature. We first formulate a nonlinear model to optimize vehicle scheduling, charging time, and charging power, to minimize the total system costs, including the usage costs of electric buses and charging costs. Then, a genetic algorithm is developed to solve this model. Finally, the proposed method is demonstrated by using the example of a transit network in Nanjing. Compared with the existing scheme based on an uncontrolled charging strategy, the proposed solution reduces the total system costs and charging costs by 7.34% and 36.51%, respectively. The findings in this paper can provide practical guidance on electric bus scheduling and promote the sustainable development of bus systems.
    Type of Medium: Online Resource
    ISSN: 0361-1981 , 2169-4052
    URL: Article
    DOI: 10.1177/03611981231178307
    Language: English
    Publisher: SAGE Publications
    Publication Date: 2023
    detail.hit.zdb_id: 2403378-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials
    SAGE Publications ; 2019
    In:  Therapeutic Advances in Musculoskeletal Disease Vol. 11 ( 2019-01), p. 1759720X1989549-
    Details
    In: Therapeutic Advances in Musculoskeletal Disease, SAGE Publications, Vol. 11 ( 2019-01), p. 1759720X1989549-
    Abstract: We aimed to systematically assess a possible association of tofacitinib therapy with cardiovascular events (CVEs) and all-cause mortality. Methods: Systematic searches of PubMed, Embase, and Cochrane Library were conducted from inception through March 2019. Randomized controlled trials in patients with immune-mediated inflammatory diseases (IMIDs) reporting safety data were included. Included studies compared tofacitinib with placebo or 5 mg tofacitinib with 10 mg tofacitinib. The primary and secondary outcome measures were all CVEs [major adverse cardiovascular events (MACEs)/venous thromboembolism events (VTEs)] and all-cause mortality. Results: 29 studies randomizing 13,611 patients were included. Compared with placebo, there was no significant increased risk of all CVEs (OR = 1.07, 95% CI 0.49–2.34), MACEs (OR 1.54, 95% CI 0.42–5.59), or all-cause mortality (OR = 1.13, 95% CI 0.26–4.95), but a decreased rate of VTEs (OR 0.03, 95% CI 0.00–0.21) in patients with IMIDs initiating tofacitinib. Meanwhile, paired comparison showed 10 mg tofacitinib twice daily was associated with a significantly lower incidence of all CVEs (OR = 0.56, 95% CI 0.33–0.96), MACEs (OR = 0.48, 95% CI 0.22–1.05), or all-cause mortality (OR = 0.47, 95% CI 0.19–1.17), but a trend toward an increase in VTEs risk (OR = 1.47, 95% CI 0.25–8.50), compared with the 5 mg regimen. Conclusion: Compared with placebo, there was no augmented risk of CVEs and all-cause mortality in patients with IMIDs following tofacitinib treatment in a short-term perspective, whereas 10 mg twice daily tofacitinib appeared to be associated with reduction in cardiovascular and all-cause mortality risks, except VTEs, relative to the 5 mg twice daily dose. Long-term studies and postmarketing risk monitoring are increasingly needed to develop a better understanding.
    Type of Medium: Online Resource
    ISSN: 1759-720X , 1759-7218
    URL: Article
    DOI: 10.1177/1759720X19895492
    Language: English
    Publisher: SAGE Publications
    Publication Date: 2019
    detail.hit.zdb_id: 2516075-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...